n.a. (FURX)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 10.82M
Div & Yield N.A. (N.A)
Furiex Pharmaceuticals Announces First Quarter 2012 Earnings Release And Conference Call

Furiex Pharmaceuticals Announces First Quarter 2012 Earnings Release And Conference Call

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) will release its first quarter 2012 financial results on Thursday, May 3, 2012, after the market closes.

Insiders Trading WPRT, H, FURX

Insiders Trading WPRT, H, FURX

The top 10 open-market insider purchases and sales filed at the SEC Thursday.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

Furiex Pharmaceuticals Inc. Stock Upgraded (FURX)

Furiex Pharmaceuticals Inc. Stock Upgraded (FURX)

Furiex Pharmaceuticals (Nasdaq:FURX) has been upgraded by TheStreet Ratings from a sell to hold.

Furiex Reports Fourth Quarter And Full Year 2011 Financial Results

Furiex Reports Fourth Quarter And Full Year 2011 Financial Results

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today reported its financial and operating results for the quarter and year ended December 31, 2011.

Furiex Announces That The European Commission Endorses Positive Opinion Of Priligy™ For The On-Demand Treatment Of Premature Ejaculation In All European Union Countries

Furiex Announces That The European Commission Endorses Positive Opinion Of Priligy™ For The On-Demand Treatment Of Premature Ejaculation In All European Union Countries

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today announced that the European Commission endorsed the positive opinion adopted by the Committee for Human Medicinal Products (CHMP) on October 18, 2011 for Priligy™...

Furiex Pharmaceuticals Announces Fourth Quarter And Full Year 2011 Earnings Release And Conference Call

Furiex Pharmaceuticals Announces Fourth Quarter And Full Year 2011 Earnings Release And Conference Call

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) will release its fourth quarter and full year 2011 financial results on Tuesday, February 21, 2012, after the market closes.

Furiex Announces Results For Phase II Trial Of PPD-10558

Furiex Announces Results For Phase II Trial Of PPD-10558

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today announced top-line results from the Phase II trial of the investigational drug PPD-10558 in patients with statin-associated myalgia, or SAM.

5 Stocks Insiders Are Snapping Up

5 Stocks Insiders Are Snapping Up

Insiders at these companies have been scooping up shares of their own stock lately.

Insiders Trading AGO, IT, FURX, AMZN

Insiders Trading AGO, IT, FURX, AMZN

The top 10 open-market insider purchases and sales filed at the SEC Monday.

Insider Buying Tipping to Bullish Side

Insider Buying Tipping to Bullish Side

There's conviction behind the buying in these particular names, so they may be a good starting point.

5 Stocks With Key Insider Buying

5 Stocks With Key Insider Buying

Insiders at these companies have been scooping up shares of their own stock lately.

Insiders Trading FURX, WFM, LHCG, GNC

Insiders Trading FURX, WFM, LHCG, GNC

The top 10 open-market insider purchases and sales filed at the SEC Tuesday.

Furiex Reports Third Quarter 2011 Financial Results

Furiex Reports Third Quarter 2011 Financial Results

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today reported its financial and operating results for the quarter ended September 30, 2011.

Furiex Acquires Full Exclusive License To MuDelta For The Treatment Of Diarrhea-Predominant IBS And Reports Positive End Of Phase II FDA Meeting

Furiex Acquires Full Exclusive License To MuDelta For The Treatment Of Diarrhea-Predominant IBS And Reports Positive End Of Phase II FDA Meeting

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced today that it has acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with...

Furiex Pharmaceuticals Study Results To Be Presented At The American College Of Gastroenterology 2011 Annual Scientific Meeting

Furiex Pharmaceuticals Study Results To Be Presented At The American College Of Gastroenterology 2011 Annual Scientific Meeting

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX), a drug development collaboration company, announced its late-breaking abstract describing results from the Phase II proof-of-concept clinical trial evaluating the safety and...

Furiex Pharmaceuticals Announces Scientific Publications For JNJ-Q2

Furiex Pharmaceuticals Announces Scientific Publications For JNJ-Q2

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today announced recent and upcoming publications and presentations about the novel investigational antibacterial drug JNJ-Q2.

Furiex Pharmaceuticals Announces Third Quarter 2011 Earnings Release And Conference Call

Furiex Pharmaceuticals Announces Third Quarter 2011 Earnings Release And Conference Call

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) will release its third quarter 2011 financial results on Tuesday, November 1, 2011, after the market closes.

Furiex Confirms Takeda Launches LIOVEL® LD And LIOVEL® HD, A Fixed Dose Combination Of NESINA® And ACTOS®, For Type 2 Diabetes In Japan

Furiex Confirms Takeda Launches LIOVEL® LD And LIOVEL® HD, A Fixed Dose Combination Of NESINA® And ACTOS®, For Type 2 Diabetes In Japan

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today confirmed that Takeda Pharmaceutical Company Limited (“Takeda”) has launched two dosages of LIOVEL ®, a fixed dose combination tablet of NESINA ® ...

Furiex Reports Positive Phase II Results For MuDelta In Treatment Of Diarrhea-Predominant Irritable Bowel Syndrome

Furiex Reports Positive Phase II Results For MuDelta In Treatment Of Diarrhea-Predominant Irritable Bowel Syndrome

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today announced successful results from its Phase II proof-of-concept clinical trial evaluating the safety and efficacy of MuDelta, an investigational oral agent for the ...

Furiex Pharmaceuticals To Present At The Stifel Nicolaus Healthcare Conference 2011

Furiex Pharmaceuticals To Present At The Stifel Nicolaus Healthcare Conference 2011

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX), a drug development collaboration company, announced that June Almenoff, M.

11 New Stocks Rated by TheStreet

11 New Stocks Rated by TheStreet

TheStreet Ratings released initial ratings on 11 U.S. common stocks in the first two weeks of August. Six of these stocks start out at 'sell' and five earned a recommendation of 'hold' from our stock model.

Furiex Pharmaceuticals Enters Into Loan Agreement For Up To $15 Million

Furiex Pharmaceuticals Enters Into Loan Agreement For Up To $15 Million

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) announced today it has entered into a loan agreement with MidCap Financial and Silicon Valley Bank to provide up to $15.

Furiex Pharmaceuticals To Present At The Wedbush 2011 Life Sciences Management Access Conference

Furiex Pharmaceuticals To Present At The Wedbush 2011 Life Sciences Management Access Conference

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX), a drug development collaboration company, announced that June Almenoff, M.

Furiex Reports Second Quarter 2011 Financial Results

Furiex Reports Second Quarter 2011 Financial Results

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today reported its financial and operating results for the quarter ended June 30, 2011.

Furiex Confirms Takeda's Resubmissions Of Alogliptin NDAs To The U.S. Food And Drug Administration

Furiex Confirms Takeda's Resubmissions Of Alogliptin NDAs To The U.S. Food And Drug Administration

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today confirmed that Takeda Pharmaceutical Company Limited has resubmitted two new drug applications (NDAs) for alogliptin to the U.

Furiex Pharmaceuticals Announces Second Quarter 2011 Earnings Release And Conference Call

Furiex Pharmaceuticals Announces Second Quarter 2011 Earnings Release And Conference Call

Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) will release its second quarter 2011 financial results on Wednesday, August 3, 2011, after the market closes.

5 Stocks With Big Insider Buying

5 Stocks With Big Insider Buying

Insiders at these companies have been scooping up shares of their own stock.

Insiders Trading FURX, CLWR, CPWM, QLIK

Insiders Trading FURX, CLWR, CPWM, QLIK

The top 10 open-market insider purchases and sales filed at the SEC Thursday.

Insiders Trading FURX, MELI, FRP

Insiders Trading FURX, MELI, FRP

The top 10 open-market insider purchases and sales filed at the SEC Friday.